AI Could Significantly Improve How Tumor Samples are Analyzed in the Lab – Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:
“NEW in Nature Medicine:
A study led by Memorial Sloan Kettering Cancer Center (MSK) and the Icahn School of Medicine at Mount Sinai suggests that AI could significantly improve how tumor samples are analyzed in the lab using a model trained to identify lung cancer mutations. The approach cut the number of molecular tests needed by up to 43% while maintaining clinical standards.
‘Our findings demonstrate the real-world clinical utility of this computational biomarker,’ says MSK pathologist Dr. Chad Vanderbilt, a co-senior author of the study.”
Title: Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection
Authors: Gabriele Campanella, Neeraj Kumar, Swaraj Nanda, Siddharth Singi, Eugene Fluder, Ricky Kwan, Silke Muehlstedt, Nicole Pfarr, Peter J. Schüffler, Ida Häggström, Noora Neittaanmäki, Levent M. Akyürek, Alina Basnet, Tamara Jamaspishvili, Michel R. Nasr, Matthew M. Croken, Fred R. Hirsch, Arielle Elkrief, Helena Yu, Orly Ardon, Gregory M. Goldgof, Meera Hameed, Jane Houldsworth, Maria Arcila, Thomas J. Fuchs, Chad Vanderbilt
Read the Full Article on Nature Medicine
More posts featuring Memorial Sloan Kettering Cancer Center.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023